Biotech | February 24, 2022
Aadi Bioscience launches Fyarro in the USA
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Zydus unveils its ‘innovation and care’ centric corporate brand identity
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
DR devices today should do more than just provide crystal clear imaging and assist during diagnosis. Hence, the ImageView Software used in DRX Compass offers upgraded cybersecurity
he financing was significantly oversubscribed with high demand from both existing and new investors.
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Subscribe To Our Newsletter & Stay Updated
